In T2D models featuring impaired insulin production induced by streptozotocin (STZ), administration of LCN2 has been shown to ameliorate pancreatic β cell proliferation, enhance insulin production, and reduce blood glucose levels (Mosialou et al. 2020). The gene discussed is INS; the disease is type 2 diabetes mellitus.